Live Breaking News & Updates on Ashling wahner

Stay informed with the latest breaking news from Ashling wahner on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Ashling wahner and stay connected to the pulse of your community

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Drs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.

Rhode-island , United-states , Florida , California , Brown-university , Miami , University-of-california-san-francisco , Ashling-wahner , Stephaniel-graff , Kellye-mccann , Reshmal-mahtani , University-of-california

CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib

Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.

Texas , United-states , North-carolina , Houston , Johnh-strickler , Ashling-wahner , Michael-leung , Margot-oneill , Arvindn-dasari , Facebook , University-of-texas-md-anderson-cancer-center , Twitter

FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer

Dr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma.

Los-angeles , California , United-states , Zeva-wainberg , Ashling-wahner , University-of-california , Linkedin , Facebook , Gastrointestinal-oncology-program , Twitter , Live-on-air , Onclive-on-air

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced/Metastatic Urothelial Carcinoma

Dr Galsky discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer.

New-york , United-states , Ashling-wahner , Matthew-galsky , Linkedin , Translational-research , Twitter , Facebook , Icahn-school-of-medicine-at-mount-sinai , Tisch-cancer-institute , Live-on-air , Medical-oncology

Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine

Drs Jacob, Van Der Wall, and Wright-Browne discuss challenges and growth opportunities they have experienced throughout their careers.

Florida , United-states , Vancem-wright-browne , Blessy-mathew-jacob , Ashling-wahner , Florida-cancer-specialists-research-institute , Facebook , Twitter , Linkedin , Live-on-air , Ana-van-der-wall , Florida-cancer-specialists

Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma

Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.

Massachusetts , United-states , Boston , California , Lipika-goyal , Chaundra-bishop , Caroline-kulhman , Katie-kelley , Ashling-wahner , Cancer-immunotherapy-program , Department-of-medicine-hematology-oncology , Taiho-pharmaceutical-co-ltd

FDA Approval Insights: Pirtobrutunib in Previously Treated CLL/SLL

Dr Davids discusses the FDA approval of pirtobrutinib for patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Boston , Massachusetts , United-states , Dana-farber-cancer-institute , Ashling-wahner , Matthews-davids , Eli-lilly , Twitter , Harvard-medical-school , Linkedin , Clinical-research , Center-at-dana-farber-cancer-institute

FDA Approval Insights: Nirogacestat in Progressing Desmoid Tumors Requiring Systemic Treatment

Dr Kasper discusses the FDA approval of nirogacestat for patients with progressing desmoid tumors; key efficacy, safety, and quality-of-life outcomes from the pivotal DeFi trial; and findings from an analysis investigating tumor volume and T2 hyperintensity changes with nirogacestat in patients enrolled in DeFi.

Heidelberg , Baden-wüberg , Germany , Ashling-wahner , Bernd-kasper , University-of-heidelberg , Facebook , Linkedin , Twitter , Live-on-air , Springworks-therapeutics , Sarcoma-unit

FDA Approval Insights: Capivasertib Plus Fulvestrant in Advanced HR+/HER2- Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

Dr Gradishar discusses the FDA approval of capivasertib plus fulvestrant for patients with advanced HR-positive, HER2-negative breast cancer harboring PIK3CA, AKT1, or PTEN alterations.

Illinois , United-states , Chicago , Williamj-gradishar , Ashling-wahner , Astrazeneca , Twitter , Northwestern-university-feinberg-school-of-medicine , Linkedin , Facebook , Department-of-medicine , Live-on-air

Santos Summarizes Key Updates From EMPOWER-Lung 1 and EMPOWER-Lung 3 With Cemiplimab in NSCLC

Dr Santos discusses findings from the EMPOWER-Lung 3 trial of cemiplimab plus chemotherapy in patients with advanced non–small cell lung cancer, as well as data from subgroup analyses of the EMPOWER-Lung 1 trial of cemiplimab monotherapy in patients with NSCLC and a PD-L1 score over 50%.

Boca-raton , Florida , United-states , Edgardos-santos , Ashling-wahner , Florida-atlantic-university-in-boca-raton , Twitter , Florida-society-of-clinical-oncology-membership-committee , Regeneron-pharmaceuticals , Linkedin , Facebook , Live-on-air